Analytical Data
-
Gene name
CD300LB
- Application
-
Alternative Names
CLM-7 (CD300 antigen-like family member B) (CMRF35-A2) (Immune receptor expressed on myeloid cells 3) (IREM-3) (Leukocyte mono-Ig-like receptor 5) (Triggering receptor expressed on myeloid cells 5) (TREM-5)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A8K4G0
-
Expression Region
18-151aa
-
Molecular Weight
18.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD300LB, a member of the CD300 family of immunoglobulin-like receptors, has gained increasing attention in immunological research due to its role in modulating immune responses. This receptor is primarily expressed on various immune cells, including myeloid lineage cells, where it influences cell activation, cytokine production, and phagocytic activity. Research indicates that CD300LB may act as a negative regulator of immune responses, particularly in the context of inflammation and autoimmune diseases. Understanding the signaling pathways and interactions of CD300LB with ligands can provide insights into its potential roles in maintaining immune homeostasis and preventing excessive immune activation. Furthermore, the exploration of CD300LB as a therapeutic target might open new avenues for treating conditions characterized by immune dysregulation, such as allergies and chronic inflammatory diseases. The generation of recombinant CD300LB proteins allows for detailed studies on its structure-function relationships and interactions with other molecules, advancing our knowledge of immune regulation mechanisms. Through such investigations, scientists aim to elucidate the therapeutic potential of modulating CD300LB activity in various clinical settings, highlighting its significance in both fundamental immunology and translational medicine.
